EMA Recommends Revoking EU Approval For Novartis’s Sickle Cell Disease Drug
Executive Summary
The results of a Phase III study did not confirm the benefits previously seen with Adakveo, the European Medicines Agency said.
You may also be interested in...
Sickle Cell Drug Development Gains Momentum Across Disease Spectrum
The recent ASH meeting began with US FDA approvals of the first genetic medicines for sickle cell disease, but doctors and biopharma companies still see a need for new oral therapies and other options.
With Sickle Cell Results For Pyrukynd, Agios Enters Increasingly Competitive Market
The company has significantly built up its pipeline since divesting its oncology business to Servier, with multiple Phase III readouts for Pyrukynd expected in 2024-2025.
EU Marketing Setback For Ipsen’s Connective Tissue Disease Drug
The European Medicines Agency is standing by its recommendation to reject Ipsen’s EU marketing authorization application for Sohonos, for treating fibrodysplasia ossificans progressiva.